• Loading stock data…

Resource Center

89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023

by Leave a Comment

Last Updated on November 12, 2023 by

[#item_full_content]




Print Friendly, PDF & Email
Spread the word

Reader Interactions

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

We provide a balanced view on small cap biotech equities

Contact Us

Address : Santa Fe, New Mexico.

Email : support@biotechwinners.com

*Disclaimer

Follow Us

Facebook Twitter Youtube Instagram

© 2022 · Bio Tech Winners · Privacy Policy

Generated by Feedzy
%d bloggers like this: